Esorella-L Capsule ER is a combination medication containing Levosulpiride 75mg and Rabeprazole 40mg, formulated for extended release to provide sustained therapeutic effects. Levosulpiride is a prokinetic and antipsychotic agent that primarily acts by blocking dopamine D2 receptors, enhancing gastrointestinal motility and alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with functional dyspepsia and gastroparesis. Rabeprazole, a proton pump inhibitor, reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, thereby promoting healing of acid-related gastrointestinal conditions like gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The combination of these two active ingredients in Esorella-L Capsule ER provides a dual mechanism of action, addressing both motility disorders and acid-related mucosal damage, making it effective in managing complex gastrointestinal disorders. This extended-release formulation ensures a gradual release of the drugs, improving patient compliance by reducing dosing frequency and maintaining consistent plasma levels. Esorella-L Capsule ER should be used under medical supervision, with attention to contraindications and potential side effects such as headache, dizziness, or gastrointestinal disturbances. It is essential to follow prescribed dosages to achieve optimal therapeutic outcomes.